Trade Alzamend Neuro, Inc. - ALZN CFD

Add to favourite

1.0048

2.9%

View detailed chart

To be able to trade stocks like this, create an account and apply for a stock listing.

Create Account

Summary
Historical Data

Trading сonditions

Spread

0.0204

Long position overnight fee

-0.023568%

Short position overnight fee

0.001346%

Overnight fee time

21:00 (UTC)

Min traded quantity

0.01

Currency

USD

Margin

5.00%

Stock exchange

United States of America

Commission on trade

Key Stats

Prev. Close	1.0348
Open	0.9948
1-Year Change	11.81%
Day's Range	0.9449 - 1.0248

Last Week
Last Month
Last Year
Last two Years
Max

Daily
Weekly
Monthly

Date	Close	Change	Change (%)	Open	High	Low
Apr 3, 2025	1.0048	0.0100	1.01%	0.9948	1.0348	0.9278
Apr 2, 2025	1.0348	0.0700	7.26%	0.9648	1.0348	0.9258
Apr 1, 2025	0.9851	0.0377	3.98%	0.9474	0.9945	0.9474
Mar 31, 2025	0.9448	-0.0500	-5.03%	0.9948	1.0048	0.9258
Mar 28, 2025	1.0448	-0.0300	-2.79%	1.0748	1.0748	0.9809
Mar 27, 2025	1.0848	0.1000	10.15%	0.9848	1.0848	0.9564
Mar 26, 2025	0.9656	-0.0211	-2.14%	0.9867	0.9944	0.9505
Mar 25, 2025	0.9898	-0.1050	-9.59%	1.0948	1.0948	0.9348
Mar 24, 2025	1.0048	-0.0200	-1.95%	1.0248	1.0248	0.9948
Mar 21, 2025	1.0048	0.0300	3.08%	0.9748	1.0148	0.9422
Mar 20, 2025	0.9698	0.0250	2.65%	0.9448	0.9748	0.9213
Mar 19, 2025	0.9310	-0.0222	-2.33%	0.9532	0.9748	0.9059
Mar 18, 2025	0.9310	0.0462	5.22%	0.8848	0.9848	0.8148
Mar 17, 2025	0.8896	0.1428	19.12%	0.7468	0.8917	0.7349
Mar 14, 2025	0.6622	-0.0226	-3.30%	0.6848	0.6848	0.6361
Mar 13, 2025	0.6658	-0.0091	-1.35%	0.6749	0.6858	0.6648
Mar 12, 2025	0.6648	-0.0101	-1.50%	0.6749	0.6799	0.6555
Mar 11, 2025	0.6748	-0.0355	-5.00%	0.7103	0.7149	0.6548
Mar 10, 2025	0.6848	-0.0700	-9.27%	0.7548	0.7548	0.6848
Mar 7, 2025	0.7348	-0.0056	-0.76%	0.7404	0.7404	0.7148

Trading calculator

Calculate your hypothetical P&L if you had opened a CFD trade on a certain date (select a date) and closed on a different date (select a date).

Trade commission

1:1
2:1
3:1
5:1
10:1
20:1

Leverage

20:1

20
100
500
1000
10000

Investment

Trade size (Leverage x Investement):

Open

Close

Short Long

For the avoidance of doubt, this calculation does not include the costs of holding a position overnight (for which there will be additional charges)

Alzamend Neuro, Inc. Company profile

About Alzamend Neuro Inc

Alzamend Neuro, Inc. is a preclinical stage biopharmaceutical company focused on developing products for the treatment of neurodegenerative diseases and psychiatric disorders. The Company's pipeline consists of two therapeutic drug candidates: AL001 and AL002. The AL001 is a cocrystal technology delivering a therapeutic combination of lithium, proline and salicylate, known as AL001 or LiProSal, through two royalty-bearing worldwide licenses from the University of South Florida Research Foundation, Inc. (licensor). AL002 is a patented method using a mutant peptide sensitized cell as a cell-based therapeutic vaccine that seeks to restore the ability of a patient’s immunological system to combat Alzheimer’s, known as AL002 or CA022W, through a royalty-bearing worldwide license from the licensor.

Financial summary

BRIEF: For the nine months ended 31 January 2022, Alzamend Neuro Inc revenues was not reported. Net loss increased from $3.8M to $8.5M. Higher net loss reflects Research and development - Bal increase from $953K to $3.2M (expense), Stock-based Compensation in SGA increase of 67% to $2.8M (expense), General and administrative - Bal increase from $547K to $1.1M (expense).

Industry:

Biotechnology & Medical Research (NEC)

3480 Peachtree Road NE,
Second Floor, Suite 103
ATLANTA
GEORGIA 30326
US